Tore Curstedt at Karolinska Institutet’s Department of Molecular Medicine and Surgery has been nominated by the European Patent Office for a Lifetime Achievement Award at the 2016 European Inventor Award ceremony for his work with 'Curosurf'
Tore Curstedt is nominated for the work he and his colleague Bengt Robertsson have done on their innovative treatment for preterm babies with respiratory distress syndrome. The method, which was introduced in 1989, has now been administered to over three million infants.
The drug developed by Curstedt is marketed under the name Curosurf and is used in 80 countries, where it is estimated to have saved the lives of over half a million preterm babies.
The nominations deadline is 31 May, and the prize ceremony will be held in Lisbon on 9 June 2016.
Read more about the prize and Curstedt’s nomination on the EPO website.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
